,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny breast04', 'breast']
impressive results #destiny breast04 #asco22 improvement of pfs and os safety profile new standard treatment in patients with her2 low metastatic breast cancer 
Medical oncologist